LOADING
Comparing JPMorgan Chase (JPM) and Merck & Company (MRK) across the Financials and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | JPM | MRK |
|---|---|---|
| Price | -- | -- |
| Change Today | +0.00% | +0.00% |
| Market Cap | $901.6B | $305.1B |
| P/E Ratio | 16.1 | 34.8 |
| Forward P/E | 15.2 | 24.4 |
| PEG Ratio | 1.77 | 6.10 |
| EPS | $20.89 | $3.55 |
| Revenue Growth (YoY) | 12.7% | 4.9% |
| Profit Margin | 33.9% | 13.6% |
| Return on Equity | 16.5% | 18.9% |
| Dividend Yield | 1.76% | 2.62% |
| Beta | 0.98 | 0.20 |
| 52-Week High | $341.91 | $130.29 |
| 52-Week Low | $276.44 | $74.18 |
| Volume | -- | -- |
JPMorgan Chase is the larger company by market capitalization. JPMorgan Chase trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. JPMorgan Chase has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.